Angiotensin II AT 1 -receptor antagonists are highly bound to plasma proteins (≥ 99%). With some antagonists, such as DuP-532, the protein binding was such that no efficacy of the drug could be demonstrated clinically. Whether protein binding interferes with the efficacy of other antagonists is not known. We have therefore investigated in vitro how plasma proteins may affect the antagonistic effect of different AT 1 -receptor antagonists.
Introduction
In recent years, several specific, orally-active, nonpeptide angiotensin II (Ang II) receptor antagonists have been developed and have become available clinically. These antagonists share a common mechanism of action, that of blockade of Ang II AT 1 -receptors.Yet, the various antagonists differ in their phar-macological profiles and these differences might sometimes affect their efficacy profile. 1, 2 One common feature of all members of the Ang II receptor antagonist class is their high binding to plasma proteins. Indeed, all antagonists are generally bound to plasma proteins, mainly albumin and α 1 -acid glycoprotein (AGP), by more than 99%. 1 This high affinity for proteins appears to be species-specific and may have important implications when extrapolating animal results to humans. 3 On the other hand, the estimation of protein binding is not straightforward; thus a clear discrimination between 99 and 99.5 or 99.9% binding cannot be established precisely by conventional methods, such as ultrafiltration or equilibrium dialysis.In addition,these measures never clearly indicate the functional influence of this binding to the pharmacological activity of the drug. An extreme example of the potential interference of protein binding with the efficacy of Ang II receptor antagonist is illustrated by the development of DuP-532.When DuP-532, a potent and selective AT 1 -receptor antagonist, was administered for the first time to normotensive subjects in order to assess its ability to blunt the pressor responses to exogenous Ang II, no antagonism could be demonstrated. 4 Yet the plasma concentrations of DuP-532 measured in these volunteers were much greater than those of losartan/EXP-3174. In addition, the compound was found to be a very potent antihypertensive agent in animals 5 and in vitro, DuP-532 and EXP-3174 (losartan's active metabolite) had similar AT 1 -receptor antagonistic activity. 4, 5 Following these initial observations, the development of DuP-532 was stopped.
The data obtained with DuP-532 suggested that the balance between the specific binding of the drug to the AT 1 -receptor and its association with non-specific binding sites,i.e.,plasma proteins,could play an important role in determining the pharmacological response to the drug. In some extreme situations, illustrated by DuP-532, the balance is such that the antagonist loses its capacity to bind to its specific receptor. 6 The goal of the present experiments was therefore to evaluate in vitro how the binding to plasma proteins may affect the degree of Ang II receptor blockade induced by various AT 1 -receptor antagonists in humans.
Methods
Most studies have been conducted in vitro using a radio-receptor assay developed recently in our laboratory. 7 In this assay, the binding of radiolabelled Ang II to a rat smooth muscle cell membrane preparation, expressing solely AT 1 -receptors, is measured. To investigate the influence of proteins on the displacement of labelled Ang II by the pharmacological compounds, 6.25% human plasma was added to the binding buffer to obtain a final protein concentration of 0.4%, which approximately corresponds in vitro, to the same proportion of plasma proteins encountered in vivo in presence of ten to hundreds ng/ml of drug, which are concentrations generally achieved at peak during antihypertensive treatment. In subsequent studies, increasing concentrations of compounds known to interact strongly with protein binding, e.g. digitoxin, warfarin, diazepam, and disopyramide, were added to the binding buffer in order to characterise the nature of the binding sites to which AT 1 -receptor antagonists are linked.
Finally, the Biacore technology, Uppsala, Sweden (BIAtechnology) has been used to investigate the interaction between a set of Ang II receptor antagonists and immobilised human serum albumin (HSA). This technique enables the realtime monitoring of the binding events between two or more molecules without the use of labels. In addition, molecules do not need to be purified. The BIAtechnology relies on the phenomenon of surface plasmon resonance (SPR), which occurs when surface plasmon waves are excited at a metal/liquid interface. Light is directed at, and is reflected from, the side of the surface not in contact with sample, and SPR causes a reduction in the reflected light intensity at a specific combination of angle and wavelength. The binding events cause changes in the refractive index at the surface layer, which are detected as changes in the SPR signal. In our experiments, the intensity of the signal obtained from the interaction of drugs with the HSA-coated surface was correlated with the HSA-binding level. Drugs were distributed among three groups corresponding to high, medium, or low HSA-binding, based on the injection of the drug at 80 µM concentration. Binding to AGP was also investigated using the same method.Warfarin was used as a positive control. This method has been used to estimate the kinetics of the interaction of five Ang II receptor antagonists with HSA, and, in particular, to characterise their dissociation rate constant (K D ) to HSA. Details of the exact methodology used in these latter experiments will be published elsewhere. Figure 1 shows the effect of four different Ang II receptor antagonists on the binding of Ang II to AT 1receptors, in the presence and the absence of proteins. The addition of human plasma induces a significant rightward shift of the displacement curve and hence an increase in the 50% inhibition constant (IC 50 ) of some, but not all, angiotensin antagonists.
Results
The addition of protein has no effect on the binding of Ang II itself. Table 1 summarises the protein-induced changes in IC 50 obtained with all antagonists tested in our laboratory.
With antagonists like losartan, tasosartan, irbesartan and telmisartan, the duration of incubation S55 PAPER Figure 1 Displacement of specific labelled angiotensin II binding in rat vascular smooth muscle cell preparations by different angiotensin II receptor antagonists in the absence ( ) or in the presence (•) of 6.25% of human plasma, corresponding to 0.4% of proteins.The IC 50 values are summarised in Table 1 does not affect the influence of proteins on the displacement curve (data not shown). However, with some other antagonists like candesartan, enoltasosartan or UR-7247, the rightward shift effect of proteins is attenuated when the incubation time is increased. Thus, as shown in Figure 2 for candesartan, this shift is maximal after 1 hour of incubation and tends to decrease when the incubation time is prolonged. This suggests that the release of candesartan from plasma proteins occurs slowly, gradually increasing the free concentration of the drug, which in turn may compete more effectively, according to the law of mass action, with labelled Ang II at the AT 1 -receptor, as indicated by the progressive decrease observed in IC 50 .
To investigate the nature of the protein binding sites, additional experiments were conducted in which digitoxin, warfarin, diazepam or disopyramide were added to the angiotensin binding assay. As expected, none of these compounds modified the curves produced by losartan, tasosartan, irbesartan or telmisartan, since the addition of protein had little, if any effect with these agents. However, warfarin and diazepam interfered significantly and dose-dependently with the displacement of radiolabelled Ang II-induced by candesartan or UR-7247.We can thus make the hypothesis, that in these conditions, warfarin and diazepam displaced the antagonists from their non-specific protein binding sites I and II of albumin, thereby increasing their ability to block AT 1 -receptors ( Figure 3 ). Using the same type of experiments, we found that enoltasosartan binds to digitoxin, warfarin and diazepam, as well as to disopyramide-sensitive protein binding sites. Interestingly, the addition of high concentrations of either digitoxin, warfarin, diazepam or disopyramide does not interfere with the binding of labelled Ang II to the AT 1 -receptor.
The BIAtechnology allowed confirmation that all AT 1 -receptor antagonists are high-level HSA binders, but showed considerable differences in AGP binding (data not shown).The albumin dissociation rate constants (K D ) of five Ang II receptor antagonists and warfarin are presented in Table 2 . Interestingly, a good relationship was found between the importance of the protein-induced rightward shift of the displacement curve (characterised by the change in IC 50 ) and the K D for albumin measured with the BIAtechnology (Figure 4 ). Table 1 Influence of the presence of proteins on the affinity for AT 1 -receptor in radio-receptor assay.
IC50 (nM) in a radio-receptor binding assay *
* ligand: 5 fmol 125 I-angiotensin II; binding buffer: Tris HCl 50 mM + MgCl 2 5 mM; +/-6.25% human plasma; 1-hour incubation at 37 o C. 
In absence of proteins In presence of proteins Fold decrease in affinity

Discussion
Like many other drugs, Ang II receptor antagonists are highly protein-bound. 1 Clinically, protein binding has been claimed to be responsible for the occurrence of drug interactions between many classes of therapeutics agents, but it is rarely considered a crucial pharmacological characteristic which may affect the efficacy of the drug. However, the observations made with DuP-532 have demonstrated that, in some conditions, protein binding may become an important limiting factor in therapeutic efficacy. The purpose of the present in vitro experiments was therefore to further examine how plasma proteins may modu-late the receptor blockade induced by various Ang II antagonists. Our observations show that the addition of proteins has little, if any, effect on the ability of some antagonists such as losartan, tasosartan, irbesartan or telmisartan to block AT 1receptors, whereas proteins interfere markedly, at the receptor level, with the antagonistic activity of other compounds such as DuP-532, enoltasosartan, UR-7247 or even candesartan. In recent years, we have conducted several clinical studies to assess the pharmacological properties of several orally-active Ang II antagonists such as DuP-532, 4 UR-7247, 8 tasosartan, 9 enoltasosartan, 9 telmisartan and candesartan. In PAPER these studies, we found that some compounds with a high in vitro affinity for AT 1 -receptors, such as DuP-532 or enoltasosartan, produced either markedly delayed or no pharmacological responses in humans, despite the fact that high plasma drug levels were achieved. Based on these observations, we have hypothesised that these compounds have a high affinity for both AT 1 -receptors and for non-specific protein-binding sites. Thus, with these agents there is direct competition between their ability to bind with specific and non-specific binding sites. Depending on the balance between these two possibilities the compounds are more or less effective in blocking AT 1receptors.
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As observed clinically, in our radio-receptor assay, the AT 1 antagonistic effects of Ang II receptor antagonists were differently affected by the addition of human plasma. The presence of proteins shifted the concentration-response curves to the right, thus increasing the IC 50 .This shift was rather small for losartan, tasosartan, irbesartan and telmisartan; a little more significant with candesartan, while the presence of plasma drastically increased the IC 50 of UR-7247, enoltasosartan and DUP-532.
To demonstrate that, in spite of the fact that all antagonists are highly protein-bound to a similar extent (>99%), the precise mechanisms may differ, additional experiments were performed with drugs known to interfere more or less specifically with some protein binding sites. Thus, warfarin interferes with site I, diazepam with site II and digitoxin with site III of albumin, 10 while disopyramide interferes with the AGP binding site. 11 With this approach, we have been able to show that enoltasosartan is markedly and dose-dependently displaced from proteins when warfarin, diazepam, digitoxin and disopyramide are added to the binding buffer. In contrast, only albumin sites I and II were involved in the protein binding of candesartan and UR-7247, whereas other Ang II receptor antagonists (losartan, tasosartan, irbesartan and telmisartan) were not significantly affected by the presence of these compounds, even at very high pharmacological concentrations.
The BIAtechnology allowed us to confirm that all AT 1 -antagonists bind at a high level with albumin, but show considerable differences in AGP binding. However, the main information brought by this technique was the determination of the dissociation rate constants (K D ) to HSA of five antagonists, chosen for their different behaviour and affinity for the AT 1 -receptor in the presence of proteins. The wide range of the K D measured in these experiments confirms that there are qualitative differences between the various antagonists in their binding to albumin. A low K D , as observed with enoltasosartan, is indicative of the presence of more stable and long-lasting AT 1receptor antagonist/albumin complexes than it is the case for losartan. Interestingly, these experiments also confirmed the observation that the AT 1 -receptor antagonists showing the greatest affinity for albumin are those that are bound through several binding sites, and that these agents are the most affected in vitro by the presence of plasma proteins.
Taken together, these results suggest that the qualitative interaction between AT 1 -receptor antagonists and proteins, and not necessarily the quantitative aspect of the binding, is an important determinant which may affect the efficacy of these drugs. A detailed characterisation of the interaction of Ang II antagonists with proteins may be of interest to improve our understanding of the peculiar pharmacodynamic behaviour of some of these agents.
The interaction of proteins and AT 1 -receptor antagonists only represents one parameter among others involved in the general pharmacological action of the drugs. Thus, the bioavailability and the volume of distribution, 12 together with the intrinsic functional inhibitory characteristics of the drug, i.e. dissociation constants from the AT 1receptor, insurmountable antagonism, etc, 13 are other parameters which determine efficacy. It is therefore difficult to evaluate the relative contribution of protein binding to the differences between antagonists.
